The Ampoules and Syringes Market size is anticipated to grow at a CAGR of 7.2% with USD 12 Bn in 2026 and is expected to reach USD 19.3 Bn in 2033. The primary drivers are defined by rising demand for injectable drug delivery systems, expansion of biologics and vaccine programs, increasing prevalence of chronic diseases, and growing adoption of prefilled syringes and safety-engineered devices. According to the World Health Organization, billions of injections are administered globally each year, highlighting critical demand for safe delivery systems. This is strengthening focus on sterile packaging, infection control, and clinical efficiency pathways.
On the basis of product type, the syringes segment is projected to account for the largest Ampoules and Syringes Market share of 68.4% in 2026. The segment’s growth is owing to its essential role in drug administration, vaccination programs, and emergency medical procedures. Syringes are extensively used across hospitals, clinics, and homecare settings due to their affordability as well as ease of use.
In June 2026, Alkem Laboratories launched semaglutide in single-shot pre-filled syringes in India, starting at INR 350, becoming the first firm to offer such delivery format. The launch aims to improve affordability and access alongside existing pen formats for diabetes and obesity treatment.

To learn more about this report, Request Free Sample
On the basis of material, the glass segment lead with a major 69.2% share in 2026. The growth is owing to its superior chemical resistance, inert nature, and compatibility with sensitive injectable drugs. The FDA pharmaceutical packaging compliance guidelines highlight glass as the preferred material for sterile injectable drug storage.
In October 2025, SCHOTT Pharma launched a 5.5 ml prefillable glass syringe designed for large-volume biologic drug delivery and homecare use. The syringe is compatible with Ypsomed autoinjectors and supports the growing demand for self-administration of chronic as well as specialty injectable therapies.
India is emerging as a major hub for pharmaceutical manufacturing innovation, particularly in sterile injectable packaging systems like ampoules and syringes. The country’s strong generics industry, expanding biologics pipeline, and government-led initiatives such as Make in India are speeding up the domestic production of high-quality glass tubing, prefilled syringes, and sterile ampoules.
In August 2025, SCHOTT expanded its India operations by launching syringe and cartridge glass tubing production in Gujarat. The facility strengthens the supply for prefillable syringes and GLP-1 injectable therapies. This development is expected to strengthen the adoption of glass ampoules and syringe components in pharmaceutical manufacturers and contract packaging organizations in India.
Safety-engineered syringes and prefilled delivery systems are transforming injectable drug administration. The use of these systems assist in reducing contamination risks, improving dosing accuracy, and minimizing needlestick injuries.
The CDC injection safety guidelines emphasize single-use syringes and sterile practices to prevent infection transmission. The FDA also highlights risks associated with unsafe injection practices and supports the sterile single-use systems in clinical environments.
In March 2024, Becton Dickinson increased the syringe production in the United States after the FDA raised quality concerns over certain China-made syringes. The firm ramped up output at its Nebraska and Connecticut facilities to support the demand amid ongoing regulatory scrutiny and supply chain adjustments. Such innovations are expected to speed up the market growth during the forecast period.
|
Current Event |
Description and its Impact |
|
EU Commission 2025 Proposal to Simplify Medical Device Regulation Framework |
|
|
FDA Quality Management System Regulation (QMSR) – Effective February 2026 (U.S.) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report

To learn more about this report, Request Free Sample
The North America region accounts for 40.1% of the market share in 2026. The region’s growth is owing to the strong healthcare infrastructure, high pharmaceutical spending, and advanced biologics adoption. The U.S. is a major contributor, with extensive vaccine distribution programs and chronic disease treatment demand. According to the CDC (2024), over 240 million vaccine doses are administered annually in the U.S., driving syringe consumption.
In October 2025, West Pharmaceutical Services launched the West Synchrony Prefillable Syringe System, a fully verified platform designed for biologics and vaccines. The system integrates components and regulatory support from a single supplier to streamline drug delivery development and accelerate regulatory submissions.
Asia Pacificis expected to witness strong growth in market over the forecast period. The region’s growth is owing to the rising immunization coverage, injectable biologics demand, and stricter injection safety enforcement across public health systems. According to the World Health Organization (WHO), unsafe injection practices contribute to an estimated 1.7 million hepatitis B infections annually worldwide, reinforcing government-led adoption of auto-disable and safety syringes in large immunization programs.
In June 2026, West Pharmaceutical Services launched the West Synchrony Prefillable Syringe System at CPHI Chin. This is strengthening integrated drug delivery solutions for biologics and vaccines in China’s expanding biopharmaceutical market.
In the United States, the Ampoules and Syringes Market is influenced by increasing adoption of prefilled syringes for biologics and vaccines, reducing contamination risks. According to FDA data from 2026, the approval of new therapeutic proteins requiring precise parenteral administration is accelerating this sector. Notably, as of June 2026, the FDA approved Ranibizumab-hkdz, a key interchangeable biosimilar available in prefilled syringes.
In January 2026, Becton Dickinson announced a USD 110 million investment to expand U.S. production of prefillable syringes in Columbus, Nebraska. The expansion includes BD Neopak glass prefillable syringe manufacturing to support biologic and GLP-1 drug delivery and strengthen domestic pharmaceutical supply chains.
Japan is expected to grow steadily due to high demand for prefillable, safety-engineered systems to manage an aging population. According to Nipro’s 73rd term IR materials (May 2026), solid sales of injection needles and vascular products in the domestic medical segment are strengthening.
In May 2026, Samsung Bioepis launched its ustekinumab biosimilar syringe in Japan under the NIPRO partnership following national insurance listing approval. The product expands access to treatments for autoimmune conditions such as plaque psoriasis and psoriatic arthritis in the Japanese market.
Some of the major key players in Ampoules and Syringes Market are Schott AG, Gerresheimer AG, Becton, Dickinson, and Company, West Pharmaceutical Services, Inc., Nipro Corporation, Vetter Pharma International GmbH, Stevanato Group, TOPAS Advanced Polymers, JSR CORPORATION., Baxter International Inc., Terumo Corporation, B. Braun Melsungen AG, Unilife Corporation, Ypsomed Holding AG, Medtronic, and Zeon Corporation
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 12 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.2% | 2033 Value Projection: | USD 19.3 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Schott AG, Gerresheimer AG, Becton, Dickinson, and Company, West Pharmaceutical Services, Inc., Nipro Corporation, Vetter Pharma International GmbH, Stevanato Group, TOPAS Advanced Polymers, JSR CORPORATION., Baxter International Inc., Terumo Corporation, B. Braun Melsungen AG, Unilife Corporation, Ypsomed Holding AG, Medtronic, and Zeon Corporation |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients